PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23169517-1 2013 PURPOSE: Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. cabozantinib 9-21 kinase insert domain receptor Homo sapiens 112-157 23169517-1 2013 PURPOSE: Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. cabozantinib 23-28 kinase insert domain receptor Homo sapiens 112-157 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 37-46 glutathione S-transferase pi 1 Homo sapiens 231-236 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 154-163 glutathione S-transferase pi 1 Homo sapiens 119-124 20654585-9 2010 These results support a mechanism of cisplatin resistance mediated by the PKCalpha-dependent serine phosphorylation of GSTP1 and its associated increased cisplatin metabolism, and suggest the potential of simultaneous targeting of GSTP1 and PKCalpha to improve the efficacy of cisplatin therapy. Cisplatin 154-163 glutathione S-transferase pi 1 Homo sapiens 119-124 18852128-1 2008 Cells expressing elevated levels of allelic variants of human glutathione S-transferase P1 (GSTP1) and/or efflux transporters, MRP1 or MRP2, were used to evaluate the role of GSTP1-1 in cisplatin resistance. Cisplatin 186-195 glutathione S-transferase pi 1 Homo sapiens 175-182 19396019-0 2009 GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling. Cisplatin 17-29 glutathione S-transferase pi 1 Homo sapiens 0-5 18852128-2 2008 These studies revealed that GSTP1-1 confers low-level resistance (1.4- to 1.7-fold) to cisplatin-induced cytotoxicity in MCF7 cells. Cisplatin 87-96 glutathione S-transferase pi 1 Homo sapiens 28-35 18852128-0 2008 Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Cisplatin 73-82 glutathione S-transferase pi 1 Homo sapiens 8-36 18852128-4 2008 To understand the mechanism by which variants of GSTP1-1 confer resistance to cisplatin, their relative abilities to catalyze conjugation of cisplatin with glutathione were examined. Cisplatin 78-87 glutathione S-transferase pi 1 Homo sapiens 49-56 18852128-4 2008 To understand the mechanism by which variants of GSTP1-1 confer resistance to cisplatin, their relative abilities to catalyze conjugation of cisplatin with glutathione were examined. Cisplatin 141-150 glutathione S-transferase pi 1 Homo sapiens 49-56 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 83-92 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-6 2008 Although these data are consistent with the idea that very low level resistance to cisplatin may be conferred by GSTP1-1-mediated cisplatin/glutathione conjugation, two observations indicate that such catalysis plays a minor role in the protection from cisplatin toxicity. Cisplatin 130-139 glutathione S-transferase pi 1 Homo sapiens 113-120 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 28-37 glutathione S-transferase pi 1 Homo sapiens 63-70 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 28-37 glutathione S-transferase pi 1 Homo sapiens 63-68 18852128-9 2008 We conclude that high-level cisplatin resistance attributed to GSTP1-1 in other studies is not likely due to catalysis of cisplatin conjugation but rather must be explained by other mechanisms, which may include GSTP1-mediated modulation of signaling pathways. Cisplatin 122-131 glutathione S-transferase pi 1 Homo sapiens 63-68 17513610-6 2007 Our results showed that GSTP1 expression was up-regulated in osteosarcoma cells when they were treated with doxorubicin or cisplatin. Cisplatin 123-132 glutathione S-transferase pi 1 Homo sapiens 24-29 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 142-151 glutathione S-transferase pi 1 Homo sapiens 40-45 18701490-0 2008 Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cisplatin 48-57 glutathione S-transferase pi 1 Homo sapiens 11-39 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 21-25 glutathione S-transferase pi 1 Homo sapiens 254-282 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 21-25 glutathione S-transferase pi 1 Homo sapiens 284-289 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 140-144 glutathione S-transferase pi 1 Homo sapiens 254-282 18701490-2 2008 By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). Cisplatin 140-144 glutathione S-transferase pi 1 Homo sapiens 284-289 18701490-8 2008 In conclusion, our findings show that GSTP1 has a relevant effect for both CDDP resistance and clinical outcome of high-grade osteosarcoma and that targeting GSTP1 with NBDHEX may be considered a promising new therapeutic possibility for osteosarcoma patients who fail to respond to conventional chemotherapy. Cisplatin 75-79 glutathione S-transferase pi 1 Homo sapiens 38-43 17593093-1 2007 AIM: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. Cisplatin 136-145 glutathione S-transferase pi 1 Homo sapiens 5-33 17593093-1 2007 AIM: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. Cisplatin 136-145 glutathione S-transferase pi 1 Homo sapiens 35-40 17593093-2 2007 The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Cisplatin 194-203 glutathione S-transferase pi 1 Homo sapiens 61-66 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 142-151 glutathione S-transferase pi 1 Homo sapiens 345-350 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 244-253 glutathione S-transferase pi 1 Homo sapiens 40-45 17513610-9 2007 The cytotoxicity assay also showed that GSTP1 suppression caused a 2.5-fold increase in cell growth inhibition resulting from doxorubicin and cisplatin treatments [the IC(50)s are approximately 0.16 micromol/L (doxorubicin) and 1.8 micromol/L (cisplatin) for parental HOS versus 0.06 micromol/L (doxorubicin) and 0.75 micromol/L (cisplatin) for GSTP1-silenced HOS]. Cisplatin 244-253 glutathione S-transferase pi 1 Homo sapiens 40-45 17513610-10 2007 Moreover, GSTP1 suppression decreased the activation of extracellular signal-regulated kinase 1/2, which is induced by cisplatin and doxorubicin. Cisplatin 119-128 glutathione S-transferase pi 1 Homo sapiens 10-15 17513610-11 2007 Taken together, these findings show that GSTP1 contributes to doxorubicin and cisplatin resistance in osteosarcoma, which may be mediated in part by the activation of extracellular signal-regulated kinase 1/2. Cisplatin 78-87 glutathione S-transferase pi 1 Homo sapiens 41-46 17513610-7 2007 GSTP1 overexpression in SAOS-2 osteosarcoma cells caused the cells to be more resistant to doxorubicin and cisplatin. Cisplatin 107-116 glutathione S-transferase pi 1 Homo sapiens 0-5 17513610-8 2007 In contrast, GSTP1 suppression in HOS cells caused more apoptosis and extensive DNA damage in response to doxorubicin and cisplatin. Cisplatin 122-131 glutathione S-transferase pi 1 Homo sapiens 13-18 17228018-11 2007 CONCLUSION: The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment. Cisplatin 84-93 glutathione S-transferase pi 1 Homo sapiens 51-56 16317430-11 2006 Testing for TS and GSTP1 polymorphisms may allow identification of gastric cancer patients who will benefit from 5-FU/cisplatin chemotherapy, sparing others the side effects of this chemotherapy. Cisplatin 118-127 glutathione S-transferase pi 1 Homo sapiens 19-24 15279901-4 2004 When we transduced the methylated oligonucleotides to A549 lung adenocarcinoma cells, methylation of the GSTP1 promoter and reduction of GSTP1 expression was induced, cell viability was reduced; however, chemoresistance against cisplatin has not clearly changed. Cisplatin 228-237 glutathione S-transferase pi 1 Homo sapiens 105-110 21533477-5 1997 The GSTP1 cDNA transfectant KB/BSO3-pi established from KB/BSO3, and also HLE/BSO1-pi and HLE/BSO2-pi established from HLE/BSO1 and HLE/BSO2, restored cellular sensitivities to cisplatin and alkylating agents to similar levels as KB and HLE cells. Cisplatin 177-186 glutathione S-transferase pi 1 Homo sapiens 4-9 21533477-6 1997 Our present results indicate that GSTP1 levels apparently limit cellular sensitivities to cisplatin and alkylating agents, suggesting that GSTP1 is a useful diagnostic marker for drug sensitivities to these agents in human cancer cells. Cisplatin 90-99 glutathione S-transferase pi 1 Homo sapiens 34-39 21533477-6 1997 Our present results indicate that GSTP1 levels apparently limit cellular sensitivities to cisplatin and alkylating agents, suggesting that GSTP1 is a useful diagnostic marker for drug sensitivities to these agents in human cancer cells. Cisplatin 90-99 glutathione S-transferase pi 1 Homo sapiens 139-144 34164774-5 2021 circ-CHI3L1.2 knockdown decreased the half-maximal inhibitory concentration (IC50) of cisplatin and the expression levels of P-glycoprotein (P-gp), multidrug-resistance protein 1 (MRP1), and glutathione-S-transferase Pi1 (GSTP1), and promoted apoptosis of cisplatin-resistant osteosarcoma cells. Cisplatin 86-95 glutathione S-transferase pi 1 Homo sapiens 191-220 15254763-3 2004 We hypothesized that head and neck squamous cell carcinoma (HNSCC) might respond differently to chemotherapeutic agents, especially cisplatin (CDDP) because of the presence of GSTP1 I105V polymorphism. Cisplatin 132-141 glutathione S-transferase pi 1 Homo sapiens 176-181 15254763-3 2004 We hypothesized that head and neck squamous cell carcinoma (HNSCC) might respond differently to chemotherapeutic agents, especially cisplatin (CDDP) because of the presence of GSTP1 I105V polymorphism. Cisplatin 143-147 glutathione S-transferase pi 1 Homo sapiens 176-181 15347473-0 2004 [Killing effect of adenovirus mediated fusion gene cytosine and deaminase uracil phosphoribosyl transferase directed by glutathione S-transferase P1 promoter on cisplatin-resistant ovarian cancer cells in vitro]. Cisplatin 161-170 glutathione S-transferase pi 1 Homo sapiens 120-148 15347473-1 2004 OBJECTIVE: To construct an adenoviral vector in which the fusion gene cytosine and uracil phosphoribosyl (UPP) transferase was directed by glutathione S-transferase P1 (GSTP1) promoter, and to investigate specific killing effect of the suicide gene system on cisplatin-resistant ovarian cancer cells. Cisplatin 259-268 glutathione S-transferase pi 1 Homo sapiens 169-174 15347473-8 2004 CONCLUSION: Recombinant adenovirus carrying CD-UPP gene driven by GSTP1 promoter has a specific killing effect on cisplatin-resistant ovarian cancer cells. Cisplatin 114-123 glutathione S-transferase pi 1 Homo sapiens 66-71 12805482-4 2003 Transfection of the GSTP1-1 antisense expression vector into a human cholangiocarcinoma cell line (HuCCT1) apparently decreased its intracellular GSTP1-1 concentration, and the sensitivity of transfectants to adriamycin (ADR), cisplatin, and alkylating agents such as melphalan and 4-hydroxyperoxycyclophosphamide (4-HC) was increased significantly, compared with that of mock transfectants. Cisplatin 227-236 glutathione S-transferase pi 1 Homo sapiens 20-27 11874074-8 2001 In the subgroup of patients that received cisplatin-based chemotherapy (n = 14) significantly higher GSTP1-1 (p = 0.01) concentrations were found in patients with recurrence compared with patients without recurrence. Cisplatin 42-51 glutathione S-transferase pi 1 Homo sapiens 101-108 9776312-0 1998 Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Cisplatin 213-222 glutathione S-transferase pi 1 Homo sapiens 94-101 7857716-1 1994 Class pi-glutathione S-transferase (GSTP-1) is one of several factors proposed to affect drug sensitivity to cisdiamminedichloroplatinum (II) (CDDP). Cisplatin 109-136 glutathione S-transferase pi 1 Homo sapiens 36-42 7857716-1 1994 Class pi-glutathione S-transferase (GSTP-1) is one of several factors proposed to affect drug sensitivity to cisdiamminedichloroplatinum (II) (CDDP). Cisplatin 143-147 glutathione S-transferase pi 1 Homo sapiens 36-42